Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-07-11-Speech-3-374"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20070711.32.3-374"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
".
Madam President, ladies and gentlemen, I would like to thank the shadow rapporteurs and the secretariat of the Committee on International Trade for the help they gave me during this work. For us, access to medicines by the poorest countries is a priority, and that includes where the international obligations we have assumed are concerned. We therefore cannot be content to blindly accept the protocol to the TRIPS agreement and believe that this will resolve the issue.
Members of the Commission, members of the Council, there are no longer sufficient generic commitments. The European Union can and must do more, and if it is not realistic to suggest renegotiating the protocol, the Council, if it wishes to obtain the assent of the European Parliament, must make a firm commitment to state that the mechanism created by the WTO decision of 30 August 2003 is only a very small part of the solution to the problem. This means ensuring that the Member States can resort to Article 30 of the TRIPS agreement in their national laws on patents, in order to authorise production and exporting, to tackle the public health needs in importing member countries.
It means restricting the Commission’s mandate in the negotiation of economic partnership agreements with the poorest countries, so that provisions are not included that go further than the TRIPS agreement. It means supporting developing countries that use the flexibilities included in the TRIPS agreement, to provide essential medicines at reasonable prices. It means supporting grouped supply strategies to achieve economies of scale in the production of generic medicines at affordable prices and to stimulate direct investment in local production facilities.
It means actively supporting the work of the World Health Organisation’s intergovernmental working group on public health, innovation and intellectual property. It means recognising that the European Union must urgently adopt additional measures to promote the transfer of technology, research, capacity-building and regional supply mechanisms for the world’s poorest regions. It means guaranteeing a specific level of funding with which to develop or construct pharmaceutical production facilities owned by regions within developing countries, and increasing overall funding for public-private partnerships undertaking research and development in medicines that are particularly important in developing countries.
We therefore believe that we have made an active contribution to this issue, the urgency of which is demonstrated to us by the pictures that reach us from the poorest parts of the world. The ball is now in the court of the Council and the Commission, and if we receive swift, precise replies, not generalities, then the European Parliament will give the requested consent without delay."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples